Ramona Doyle
First SEC filing: April 15, 2021 · Latest: April 15, 2021
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| May 16, 2022 | RXRX | F 10b5-1 | 832 | $5.67 | $4,717 | 121,110 Direct | -0.68% | Disposed | -27.3% (price as of 2026-10-02) |
| March 31, 2022 | RXRX | M | 9,072 | · | · | 669,356 Direct | -1.34% | Disposed | (price as of 2026-10-02) |
| March 31, 2022 | RXRX | M | 9,072 | $2.48 | $22,499 | 121,942 Direct | +8.04% | Acquired | 66.1% (price as of 2026-10-02) |
| Feb. 28, 2022 | RXRX | M | 15,625 | · | · | 678,428 Direct | -2.25% | Disposed | (price as of 2026-10-02) |
| Feb. 28, 2022 | RXRX | M | 15,625 | $2.48 | $38,750 | 112,870 Direct | +16.07% | Acquired | 66.1% (price as of 2026-10-02) |
| Feb. 4, 2022 | RXRX | A | 4,784 | · | · | 4,784 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 4, 2022 | RXRX | A | 76,998 | · | · | 76,998 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 4, 2022 | RXRX | F | 981 | $11.40 | $11,183 | 97,245 Direct | -1.00% | Disposed | -63.9% (price as of 2026-10-02) |
| Feb. 4, 2022 | RXRX | A | 2,392 | · | · | 98,226 Direct | +2.50% | Acquired | (price as of 2026-10-02) |
| Feb. 4, 2022 | RXRX | A | 38,499 | · | · | 95,834 Direct | +67.15% | Acquired | (price as of 2026-10-02) |
| Jan. 31, 2022 | RXRX | M 10b5-1 | 15,625 | · | · | 694,053 Direct | -2.20% | Disposed | (price as of 2026-10-02) |
| Jan. 31, 2022 | RXRX | M 10b5-1 | 15,625 | $2.48 | $38,750 | 57,335 Direct | +37.46% | Acquired | 66.1% (price as of 2026-10-02) |
| Jan. 3, 2022 | RXRX | M 10b5-1 | 40,322 | · | · | 709,678 Direct | -5.38% | Disposed | (price as of 2026-10-02) |
| Jan. 3, 2022 | RXRX | M 10b5-1 | 40,322 | $2.47 | $99,595 | 40,322 Direct | · | Acquired | 66.8% (price as of 2026-10-02) |
| April 20, 2021 | RXRX | C | 750,000 | · | · | 750,000 Direct | · | Acquired | (price as of 2026-10-02) |
| April 20, 2021 | RXRX | C | 750,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 31, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock | $2.48 | Dec. 30, 2030 | 9,072 | Disposed |
| Feb. 28, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock | $2.48 | Dec. 30, 2030 | 15,625 | Disposed |
| Feb. 4, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock | $11.40 | Feb. 4, 2032 | 4,784 | Acquired |
| Feb. 4, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock | $11.40 | Feb. 4, 2032 | 76,998 | Acquired |
| Jan. 31, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock | $2.48 | Dec. 30, 2030 | 15,625 | Disposed |
| Jan. 3, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock | $2.47 | Dec. 30, 2030 | 40,322 | Disposed |
| April 20, 2021 | RXRX | Stock Option (Right to Buy) | Class A Common Stock [F2] | $2.47 | Dec. 30, 2030 | 750,000 | Acquired |
| April 20, 2021 | RXRX | Stock Option (Right to Buy) | Common Stock [F2] | $2.47 | Dec. 30, 2030 | 750,000 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| April 15, 2021 | RXRX | Stock Option (Right to Buy) | 750,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2020 | $3,666 | · | · | $1,134,331 | · | · | · | $1,137,997 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.